Loading...
Help
Login
Busy
Search
epSOS - Issues
 
Select object
Results (1 / 1)
Id Issue Status Priority Type Date Assigned To Label
101templates for Normal Dosing, split dosing and combination medicationDeferredLowRequest for Information/Education2017-05-17 13:54:38Christof Gessner
 
 M2 
 
Request for Information/Educationtemplates for Normal Dosing, split dosing and combination medication
Idepsos-issue-101
StatusDeferred
PriorityLow
Last Tracking2017-05-17 13:54:38  by  Giorgio Cangioli
Current AssigneeChristof Gessner
Current Labels
    
 (M2) Milestone 2 
    
Concerns
Template
Medication Item (1.3.6.1.4.1.12559.11.10.1.3.1.3.4)
/
/
Template1.3.6.1.4.1.12559.11.10.1.3.1.3.4 (2013-12-20) Medication Item
StatusDraft

/
-
/
-

Events
TrackingDeferred2017-05-17 13:54:38: Tracking by Giorgio Cangioli
    
 M2 
Description
In case to be reconsidered for future discussion
TrackingOpen2016-03-01 12:48:46: Tracking by Giorgio Cangioli
    
 M2 
Description
Look at the ELGA medication specs where they have description about it
Assignment2015-11-24 18:48:50: Assigned To Christof Gessner by Dr. Kai U. Heitmann
    
 M2 
TrackingOpen2015-11-24 18:42:22: Tracking by Dr. Kai U. Heitmann
    
 M2 
Description
The set of template IDs A, B, C etc here used in an instance mean: My instance is conformant to Template A, B and C etc.

What the optional template IDs mean here is the following (one as an example):

IF my instance is A "normal" <substanceAdministration> act that may not contain any subordinate <substanceAdministration> acts
THEN I must indicate that in my instance by mentioning template ID 1.3.6.1.4.1.19376.1.5.3.1.4.7.1
ELSE don't mention it (i.e. my instance fragment is NOT a "normal substanceAdministration"

Make this the thing more clear?

Assignment2015-11-24 17:24:00: Assigned To Dr. Kai U. Heitmann by Christof Gessner
    
 M2 
TrackingOpen2015-11-24 17:23:59: Tracking by Christof Gessner
    
 M2 
Description
Finding:

- three template IDs are given as optional

Suggestion:

- seeking clarification if that is the correct way to express this. Are the templates mutually exclusive? Any formal rules to be added?

Further explanation:

-

    
Labels
PreviewCodeHTML colorDisplay NameDescription
 
 TBA 
TBATBATo be approved
To be discussed and approved
 
 M1 
M1M1Milestone 1
Milestone 1 – before the EXPAND-athon 9-12 December 2015 Lisbon
 
 M2 
M2M2Milestone 2
Milestone 2 – final results to be delived at the end of EXPAND
 
 M3 
M3M3Milestone 3
Milestone 3 – end of the HL7 International Project
 
 M4 
M4M4Milestone 4
Milestone 4 – for consideration in the future / desiderata
 
 WJ 
WJWJChanges Word/JIRA
Changes in the Word Specification/Open a JIRA issue
 
 TID 
TIDTIDTemplate ID
Template-ID changes throughout the specification